Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | PIK3R2 | O00459 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12688802 | 0.97 | PIK3CD (0.64) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL4413968 | 0.97 | PIK3CD (0.64) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL179580 | 0.97 | PIK3CD (0.64) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL9884260 | 0.91 | PIK3R1 (0.52) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL9884268 | 0.91 | PIK3R1 (0.52) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL9884261 | 0.91 | PIK3R1 (0.52) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL9884286 | 0.89 | PIK3R1 (0.52) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL19768820 | 0.89 | PIK3R1 (0.52) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL12688644 | 0.88 | PIK3CD (0.63) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 | |
| SCHEMBL9884374 | 0.88 | PIK3R1 (0.51) | PIK3CDPIK3CGABCB11TBXA2RPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | PIK3CD 4/4885PIK3CG 6/4885ABCB11 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.